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ABSTRACT 
Multiple myeloma (MM) is a malignant disorder characterized by the proliferation of plasma cellsand the second 
most common hematological standing next to lymphoma. Multiple myeloma patients commonly present with 
defects in numbers and function of various   immune cells including dendritic cells ,B cells,Tcells and natural kill 
cells[23].Interleukin- 35 (IL-35) is a novel anti-inflammatory cytokine suppressing the immune response through 
the expansion of regulatory T cells and suppression of Th17 cell development.The present study aimedto 
investigate the possible role of IL-35 in pathogenesis of MM and its relation withimmunoglobulins such as 
IgA,IgG and IgM.Forty Iraqis patients with multiple myeloma(G1,G2) and twenty healthy individuals as a 
control group (G1)were enrolled in this study.Whole blood used for determination of  hemoglobin. Serum 
samples were used for determination of albumin,total protein using standard procedures of the biochemistry 
laboratory of hospital. Also immunoglobulin's (IgA,IgG,IgM) and IL-35 were determined in serum.The results 
revealed a significant increasing in urine total protein ,ESR,creatinine ,uric acid ,BUN, and TP in  patients 
groups(G2,G3) comparing to control group(G1) while a   significant decrease in albumin and Hb  were found in  
patients groups comparing to control .Also a significant differences  was observed in calcium concentration in 
G3  compared to G2 while there are no differences  was observed between G2 and G1 . The results shown highly 
significant increase in IgA,IgG, IgM and  IL-35,in  patients groups comparing to control group. Also a 
significant  differences were noticed in G3 comparing to G2. A highly significant positive correlation between 
IL-35 and IgA was noted in G2  and G3. Also a highly significant positive correlation between IL-35 and IgG 
levels was noticed in G2 and G3. Moreover a significant negative correlation founded between IL-35  andIgM in 
G2  and  G3 .A conclusion could be drown from this study for the first time that MM patients showed increasing 
in IL-35  levels so, it may be considered as a novel cytokine involved in the pathogenesis of MM.  
Keyword:IL-35,Multiple Myeloma,Immunoglobulines. 
 
INTRODUCTION 
Multiple myeloma(MM) is a monoclonal post –germinal center tumor that has phenotypic features of 
plasmablasts / plasma cells and usually localize at multiple sites in the bone marrow and is  the second most 
common hematological standing next to lymphoma[1[. Multiple myelomais clinically characterized by ≥ 10% of 
plasma cell infiltration in the bone marrow and presence of hyperglycemia ,renal disorder ,anemia, and bone lytic 
lesions[2].  
Interleukin (IL)-35 is a novel heterodimeric cytokine in the IL-12 family that is  comprised of an IL-12p35 
subunit and an IL-12p40  related protein subunit  [3,4]. IL-35 functions through IL-35R and has a potent 
immune-suppressive activity. Although IL-35 was demonstrated to be produced by regulatory T cells, gene-
expression analysis revealed that it is likely to have a wider distribution, including expression in cancer cells[5-
7].Some cytokines of the IL-12 superfamily are predominantly produced by antigen presenting cells in response 
to microbial or host immune stimuli and are involved in the regulation of immune responses against infections 
and tumor development[8,9] .  
    Other clinical study support the concept that some members of IL-12 may represent a novel, promising 
therapeutic agent for patients affected by different oncologic diseases including potentially MM ,based upon is 
documented multifunctional activity[10,11].  
Recently, several research groups analyzed Treg cells in multiple myeloma. So far, Treg cells data in multiple 
myeloma are conflicting. Study from Prabhala et al and Gupta et al [12,13] reported decreased frequency of 
peripheral blood Treg cells in multiple myeloma when compared to control group . Both studies confirmed that 
FoxP3 expression was reduced in myeloma patients. Most studies in myeloma agree that Treg cells efficiently 
suppress both autologous and allogeneic responder cells (CD4+CD25-) similarly to healthy subjects[14-
16].Synonymous with differential expression, the IL-12 cytokine family also exhibits distinct functional 
differences. While IL-12, IL-23, and IL-27 share the common feature of inducing interferon-γ (IFNγ) production 
and promoting T-helper 1 (Th1) cell differentiation and proliferation, they act differentially on subsets of T cells 
and with different kinetics. In contrast, IL-35 appears to function solely in an anti-inflammatory fashion by 
inhibiting T-cell proliferation and perhaps other parameters  [17,18]. 
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 The aimed of the present study is to investigate the possible role of IL-35 in pathogenesis of MM  and its 
relation withimmunoglobulins(IgA,IgG and IgM). 
 
MATERIALS AND METHODS 
Fasting blood  samples were obtained from forty Iraqis patients with multiple myeloma and twenty healthy 
individuals as a control group (G1) which enrolled in this study .Patients were divided into two stages(G2,G3) 
according to  Durie-Salmon staging system [19]which attended Baghdad Teaching hospital.Whole blood used 
for determination of  heamoglobin. Serum samples were used for determination of albumin ,total protein using 
standard procedures of the biochemistry laboratory of hospital.Immunoglobulins (IgA,IgG,IgM)  determined by 
Riaimmunodiffusion (RID) method [20] using kit from LTA s.r.l. (Italy). 
  Serum IL-35 levels were measured using specific enzyme-linked immunosorbent assay ( ELISA) kit 
(CUSABIO Human IL-35 for in vitro quantitative measurement) ,according to the manufactures protocol. 
The data was expressed as mean ± SD. The comparison between patients group and control group were analyzed 
by using student t-test. Pearson
,
s correlation coefficient was used to examine between IL-35 and 
immunoglobulins in patients group. P-value of < 0.001   and   < 0.05 were considered highly significant and 
significant respectively. 
 
RESULTS AND DISCUSSION 
Descriptive and diagnostic parameters for the three studied groups(C,G1,G2) are shown in table (1). The results 
revealed a significant increasing in urine total protein ,ESR,creatinine ,uric acid ,BUN, and TP in  patients 
groups(G2,G3) comparing to control group(G1) while a   significant decrease in albumin and Hb  were found in  
patients groups comparing to control .Also a significant differences  was observed in calcinm concentration in 
G3  compared to G2 while there are no differences  was observed between G2 and G1 .  
 
Table (1): Descriptive and diagnostic parameters for the three studied groups 
         Groups 
Parameters 
        G1 
       n=20 
      G2 
    n=20 
     G3 
     n=3 
P-
value 
 
P*-
value 
P**-
value  
Age(year) 58.5 ± 6.4 56.5    8.4 58.4    8.3 NS NS NS 
Urine total  
protein (mg/24 
hours) 
 
      150 
2400, 
M protein κ 
3000, 
M protein κ 
HS HS S 
Amyloid  Negative Positive Positive ------- ------- ------- 
Monoclonal band -------- Mband, IgGκ κ in  in 
serum  
MbandIgG κ in 
serum and 
urine  
------- ------- ------- 
ESR (mm in 1st hr) 12  ±  3.4 50 ± 15.9 64 ± 20.33 HS HS S 
Hb(g/dl) 13.6 ±0.86 9.1 ± 2.3 7.66 ± 2.12 HS HS S 
Calcium(mmol/L)  2.3 ±0.54 2.4  ± 0.6 5.3  ± 1.54 NS   S S 
Creatinine(µmol/L) 62  ±  18.1 88.4 ±  25.6 105.2± 30.1 S HS HS 
Uric acid(µmol/L) 299 ±   68 433  ±  125 533  ± 152 HS HS S 
BUN(mmol/L)  5 ±  1.45 7.1  ±2.5 8.9± 2.41 S HS S 
 TP( g/dl )   7.5±   0.4 8.5  ± 2.4 9.9 ± 3.1 S S S 
Albumin( g/dl ) 5.25 ±  
1.45 
4.33  ± 1.26 3.25 ±  1.11 S HS NS 
S Significant (P < 0.05),HS highly significant(P <  0.001),  NS  no significant(P≥ 0.05)  
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The results in table (2) shown the levels of  IgA,IgG, IgM and  IL-35. The results revealed highly significant 
increase in IgA,IgG,IgM and  IL-35,in  patients groups comparing to control group. Also a significant  
differences were noticed in G3 comparing to G2.  
 
Table 2: levels of   IgA,IgG, IgM and  IL-35  in all studied groups. 
      Groups 
 
Parameters 
        G1 
       n=20 
        G2 
       n=20 
        G3 
 n=20  
P-value P*-value P**-value 
IgA(mg/dl) 
 
173.85  15.12 204.15   49.63 352.2   72.69 HS HS   S 
 
IgG(mg/dl) 270.2    52.57 
 
305.45   52.44 410.45  60.23    S HS   S 
IgM(mg/dl)  
 
149.9   8.28 270.95  42.1 349    40.37   HS HS S 
IL-35(pg/ml) 
 
23.21   2.12 45.87    2.9 69.9569.95  4.28 HS HS  HS 
 
Ahighly significant positive correlation between IL-35 and IgA was noted in G2(r=0.408,p<0.001) and G3 ( r= 
0.405 , p<0.0001) (figures 2A,2B) .  
 
 
 
                          1A                                                                                                   1B              
Figure 1: Correlation between serum levels of IL-35 and IgA in G2(1 A) and G3 (1B)of MM patients 
Journal of Natural Sciences Research                                                                                                                                                www.iiste.org 
ISSN 2224-3186 (Paper)   ISSN 2225-0921 (Online) 
Vol.3, No.15, 2013 
 
36 
 
 
Also a highly significant positive correlation between IL-35 and IgG levels was noticed in G2 (r= 0.139, p< 
0.001) and G3 (r= 0.102,p<0.001) (figure 2A, 2B). 
 
 
                                         2A                                                                                2B                                                                     
Figure (2) :correlation between serum levels of IL-35 and IgG in G2 (2A)and  G3 (2B) ofMM patients. 
 
Moreover a significant negative correlation founded between IL-35  andIgM in G2(r=- 0.456 ,p<0.05 )   and  G3 
(r=0.358 ,p<0.05 ) (figures 3A,3B).  
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                  3A                                                                             3B 
Figure 3: Correlation between serum levels of IL-35 and IgM in G2 (A) and G3 (B) ofMM patients. 
 
Pathogenesis of MM  is complex and dependent on the interactions between tumor cells and their 
microenvironment[8].Tumors grow within an intricate network of epithelial cells, vascular and lymphatic 
vessels, cytokines and chemokine
,
s, and infiltrating immune cells. Different types of infiltrating immune cells 
have different effects on tumor progression, which can vary according to cancer type[21].Multiple myeloma 
patients commonly present with defects in numbers and function of variousimmune cells including dendritic 
cells ,B cells,Tcells and natural kill cells[22].  Previous work indicated that, like IL-27,and  IL-35 may be an 
immunomodulation at the feta-maternal border[7]. 
Most of the studies strongly suggest that myeloma patients Treg cells are functional in suppressing the 
conventional T cell proliferation,and this suppressive function encourages the immune impairments and 
dysfunctions. However, Treg cells suppressive function could be appreciated in the case of graft versus host 
disease where donor cells require engraftment to ensure the anti-tumor effects [18]. All three of the original 
family members, IL-12, IL-23, and IL-27, were initially described as pro-inflammatory/stimulatory cytokines, 
promoting T-cell proliferation and cytokine production[23].IL-35 is a novel anti-inflammatory cytokine 
suppressing the immune response through the expansion of regulatory T cells and suppression of Th17 cell 
development[24].Another study indicate that IL-27 is important for anti-parasite immunity against L. major and 
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IL-35 suppresses this immunity, the net effect of losing both IL-27 and IL-35 might be susceptibility to the 
infection, at least during the early phase of infection[25]. 
The recent study found that both IL-35 subunits were expressed concurrently in most human cancer cell lines 
compared to normal cell lines. In addition, we found that TNF-α and IFN-γ stimulation led to increased IL-35 
expression in human cancer cells. Furthermore, over-expression of IL-35 in human cancer cells suppressed cell 
growth in vitro, induced cell cycle arrest at the G1 phase, and mediated robust apoptosis induced by serum 
starvation, TNF-α, and IFN-γ stimulation . In conclusion, this results reveal a novel functional role for IL-35 in 
suppressing cancer activity, inhibiting cancer cell growth, and increasing the apoptosis sensitivity of human 
cancer cells through the regulation of genes related to the cell cycle and apoptosis[4]. 
CONCLUSION 
The results revealed an increasing in the level of IL-35 in MM patients.Also,the positive relation of MM with 
immunoglobulins reflect the possible relation of IL-35 with immunesystem.Therefore,further studies are required 
to investigate the precise effect and the signaling transduction mechanisms of IL-35 in the MM process . 
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